TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess the Clinical Efficacy of Donidalorsen (Also Known as IONIS-PKK-LRx and ISIS 721744) in Participants With Hereditary Angioedema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of HAE-1/HAE-2 (for inclusion in Part A) or HAE-nC1-INH (for inclusion in Part B)~* Participants must have experienced a minimum of 2 HAE attacks (assessed by the Angioedema Activity Score \[AAS\] and confirmed by the investigator) during the screening period~* Access to, and the ability to use, ≥ 1 acute medication(s) to treat angioedema attacks~Exclusion Criteria:~* Anticipated use of short-term prophylaxis for angioedema attacks for a pre-planned procedure during the screening or study periods~* Concurrent diagnosis of any other type of recurrent angioedema, including acquired or idiopathic angioedema~* Known history of or positive test for human immunodeficiency virus (HIV), hepatitis C, or chronic hepatitis B~* Malignancy within 5 years, except for basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix that has been successfully treated~* Treatment with another investigational drug or biological agent within 1 month or 5 half-lives, whichever is longer, of screening~* Exposure to any of the following medications:~  * Angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing medications with systemic absorption (such as oral contraceptive or hormonal replacement therapy) within 4 weeks prior to screening~ * Chronic prophylaxis with Lanadelumab within 10 weeks prior to screening~ * Oligonucleotides (including small interfering ribonucleic acid \[RNA\]) within 4 months of screening (if single dose received) or within 12 months of screening (if multiple doses received)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part A: Placebo (Type: PLACEBO_COMPARATOR): Participants with hereditary angioedema type I/type II (HAE-1/HAE-2) received placebo subcutaneously (SC) every 4 weeks at Weeks 1, 5, 9, and 13.
- Part A: Donidalorsen 80 mg (Type: EXPERIMENTAL): Participants with HAE-1/HAE-2 received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.
- Part B: Donidalorsen 80 mg (Type: EXPERIMENTAL): Participants with hereditary angioedema with normal C1-inhibitor (HAE-nC1-INH) received donidalorsen, 80 mg, SC, every 4 weeks at Weeks 1, 5, 9, and 13.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation for Management of Drug-Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Women and men are eligible. Women of reproductive age should apply effective contraception.~* Age ranges from 20 years (inclusive) to less than 70 years.~* Patients should have essential hypertension.~* Treatment-resistant hypertension in patients taking a stable drug regimen for at least 4 weeks consisting of 3 or more antihypertensive medications from different classes, including a diuretic.~* Under maximal therapy, office blood pressure should be ≥140/90 mmHg and the 24-h ambulatory blood pressure should be 130 mm Hg systolic or 80 mm Hg diastolic or higher.~* eGFR must be ≥ 60 mL/min/1.73 m2.~* The patients should accept to have adherence checked before randomisation and during supervised follow-up, but both patients and doctors will remain blinded to the results;~* Informed written consent.~Exclusion criteria:~* Suboptimal clinical context, because of recent history or concurrent disease.~* Isolated systolic and diastolic hypertension.~* Body-mass index ≥ 40kg/m2.~* The anatomy of the renal arteries is suboptimal for renal denervation.~* Pregnancy.~* Alcohol or substance abuse or psychiatric illnesses.~* Participation in other study.~* The clinical context is suboptimal for renal denervation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: OTHER): Standard antihypertensive drug treatment
- Intervention group (Type: EXPERIMENTAL): Renal denervation plus standard antihypertensive drug treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Dexrazoxane in Treating Children With Hodgkin's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven Hodgkin's disease of the following stages: Stages IIB, IIIB or IV~PATIENT CHARACTERISTICS: Age: 21 or under Performance status: Not specified Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Bilirubin less than 2 times upper normal limit Renal: Not specified Other: Not pregnant~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No prior chemotherapy Endocrine therapy: Less than one week of steroids for management of airway complications Radiotherapy: No prior radiotherapy except emergency radiation to the mediastinum Surgery: Not specified

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Patients assigned to arm I receive only these drugs.
- Arm 2 (Type: EXPERIMENTAL): Patients are randomized to one of two treatment arms. All patients receive 3 courses of chemotherapy consisting of doxorubicin hydrochloride and etoposide on days 0 and 1, bleomycin sulfate and vincristine sulfate on days 0 and 7, cyclophosphamide on day 0, and prednisone on days 0-6. Filgrastim (G-CSF) is administered on days 5-6 and 8-19. Each course is 21 days in length. Dexrazoxane hydrochloride on days 0, 1, and 7

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Patient-adjusted Versus Physician-adjusted Titration of BIAsp 30 Combined With Metformin in Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with type 2 diabetes for a minimum of 12 months prior to screening~* Currently treated with a NPH insulin for at least 3 months prior to screening~* Stable treatment (no change in dose or regimen) with a total daily dose of at least 1500 mg metformin or maximum tolerated dose (minimum 1000 mg) ± additional OAD treatment. The metformin treatment must have been stable for at least 2 months prior to screening~* HbA1c between 7.0% and 10.0% (both inclusive). (One re-test within one week of screening visit is allowed. The last sample will be conclusive.)~* Body Mass Index (BMI) below or equal to 40.0 kg/m\^2~* Able and willing to eat at least 2 main meals each day during the trial~* Able and willing to adhere to the protocol including compliance with performance of self measured plasma glucose (SMPG), injection regimen and titrating themselves according to the protocol~* Experience in performing self-measured plasma glucose (SMPG)~Exclusion Criteria:~* Treatment with any thiazolidinedione (TZD) and Glucagon-like peptide-1 (GLP-1) receptor agonists or pramlintide within the last 3 months prior to screening~* Impaired hepatic function defined as alanine aminotransferase (ALAT) above or equal to 2.5 times upper referenced limit. (One re-test within one week of screening visit is allowed. The last sample will be conclusive.)~* Impaired kidney function with serum creatinine above or equal to 133 µmol/L (1.5 mg/dL) for males and above or equal to 124 µmol/L (1.4 mg/dL) for females. (One re-test within one week of screening visit is allowed. The last sample will be conclusive.)~* Cardiac problems or uncontrolled treated/untreated severe hypertension (defined as systolic blood pressure above or equal to 180 mmHg and/or diastolic blood pressure above or equal to 100 mmHg)~* Previous use of pre-mixed insulin products (pre-mixed insulin analogues or pre-mixed human preparations)~* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic episode, during the last 12 months) or hypoglycaemic unawareness as judged by the Investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Known proliferative retinopathy or maculopathy requiring treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subject-driven titration (Type: EXPERIMENTAL): None
- Investigator-driven titration (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Remimazolam Bolus for General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 12.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 19 years old or older, with American Society of Anesthesiologists Physical Status 1-3, and scheduled for general anesthesia~Exclusion Criteria:~1. Patients scheduled for liver surgery~2. Uncontrolled hypertension~3. Uncontrolled diabetes mellitus~4. Liver disease~5. Kidney disease~6. Intolerance or hypersensitivity to benzodiazepine~7. Addiction~8. Glaucoma~9. Heart failure~10. Peripheral vascular disease~11. Obstuctive lung disease~12. Patients scheduled for regional anesthesia before general anesthesia~13. Pregnancy

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (0.02 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.02 mg/kg will be infused in patients aged\<65.
- 2 (0.07 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.07 mg/kg will be infused in patients aged\<65.
- 3 (0.12 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.12 mg/kg will be infused in patients aged\<65.
- 4 (0.17 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.17 mg/kg will be infused in patients aged\<65.
- 5(0.22 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.22 mg/kg will be infused in patients aged\<65.
- 6(0.27 mg/kg, age<65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.27 mg/kg will be infused in patients aged\<65.
- 7 (0.02 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.02 mg/kg will be infused in patients aged≥65.
- 8 (0.07 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.07 mg/kg will be infused in patients aged≥65.
- 9 (0.12 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.12 mg/kg will be infused in patients aged≥65.
- 10 (0.17 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.17 mg/kg will be infused in patients aged≥65.
- 11 (0.22 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.22 mg/kg will be infused in patients aged≥65.
- 12 (0.27 mg/kg, age≥65) (Type: ACTIVE_COMPARATOR): Remimazolam of 0.27 mg/kg will be infused in patients aged≥65.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Part 1: Eligible to receive any IEC therapy for any approved indication.~* Part 2: Eligible to receive Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.~* Eastern Cooperative Oncology Group performance status 0 to 1.~* Willingness to avoid pregnancy or fathering children~Exclusion Criteria:~* Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.~* Evidence of active hepatitis B virus or hepatitis C virus infection.~* Known human immunodeficiency virus.~* Active acute or chronic graft-versus-host disease requiring systemic therapy.~* Concurrent use of chronic systemic steroids or immunosuppressant medications.~* Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy.~* Known history or prior diagnosis of immunologic or inflammatory/autoimmune disease affecting the central nervous system (CNS) and unrelated to their disease under study or previous treatment.~* Clinically significant or uncontrolled cardiac disease.~* Acute lymphoblastic leukemia participants with protocol-defined CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia.~* Diffuse large B-cell lymphoma participants must have no signs or symptoms of CNS disease or detectable evidence of CNS disease; participants who have been previously treated for CNS disease but have no evidence of disease at screening are eligible.~* Laboratory values at screening outside the protocol-defined ranges.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Part 1: Open Label Itacitinib Once Daily (Type: EXPERIMENTAL): During Part 1, all participants receive itacitinib 200mg once daily (open label) for 30 days. The study population will include participants receiving any approved IEC for an approved indication.
- Part 2: Double-Blind Itacitinib Twice Daily (Type: EXPERIMENTAL): During Part 2, participants will be randomized to receive itacitinib 200mg or placebo twice daily for 30 days. The study population also includes participants who are receiving Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Multi-center Study to Transplant Hepatitis-C Infected Kidneys

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Recipient Inclusion Criteria:~* Estimated glomerular filtration rate(eGFR) \< 15 ml/min/1.73 m2~* Listed for an isolated kidney transplantation~* Able to understand and adhere to the study visit schedule and all other protocol requirements, and must voluntarily sign and date an informed consent~* No available medically acceptable, compatible living kidney donor~* Subject must agree to use an effective method of birth control per protocol specifications~Recipient Exclusion Criteria:~* History of severe, life-threatening or other significant sensitivity to immunosuppressants utilized in kidney transplant~* Female who is pregnant, breastfeeding, or is planning to become pregnant during the course of the study~* History of HIV~* HCV RNA positive~* HBV surface Ag-positive or detectable HBV DNA~* Primary focal segmental glomerulosclerosis (FSGS) or disease process with increased risk of causing early graft failure as assessed by the transplant nephrologist and/or investigator team~* Presence of clinically significant liver disease~* Transplant candidate requiring antibody desensitization protocol for transplantation~* Most recent calculated panel reactive antibody (cPRA) \>80%.~* Prior recipient of a non-renal solid organ transplant~Donor Organ Inclusion Criteria~* Deceased donor organ with kidney donor profile index (KDPI) ≤0.85~* HCV RNA-positive~Donor Organ Exclusion Criteria~* Known prior HCV treatment with direct acting antiviral medication~* HIV RNA-positive~* HBV Surface antigen-positive or HBV DNA-positive

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment with glecaprevir/pibrentasvir Fixed Dose Combination (Type: EXPERIMENTAL): 8 weeks of HCV treatment with combination tablet of glecaprevir and pibrentasvir

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of Two Doses of Novartis Meningococcal Serogroup B Recombinant Vaccine in Adolescents Aged 11-17 Years.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adolescents 11-17 years of age inclusive who have given their written assent and whose parent or legal guardian has given written informed consent at the time of enrollment;~2. Available for all the visits scheduled in the study (i.e. not planning to leave the area before the end of the study period);~3. In good health as determined by the outcome of medical history, physical examination and clinical judgment of the investigator;~4. With a negative urine pregnancy test (for female subjects only).~Exclusion Criteria:~1. History of any meningococcal vaccine administration;~2. Current or previous, confirmed or suspected disease caused by N. meningitidis;~3. Household contact with and/or intimate exposure to an individual with any laboratory confirmed N. meningitidis infection within 60 days of enrollment;~4. Pregnancy or nursing (breastfeeding) mothers;~5. Female subjects who have not used or do not plan to use acceptable birth control measures, for the 2 months duration of the study;~6. Any serious chronic or progressive disease;~7. Family members and household members of research staff;~8. Any condition which in the opinion of the investigator may interfere with the evaluation of the study objectives;~9. Significant acute or chronic infection within the previous 7 days or fever within 3 days prior to enrolment;~10. Antibiotics within 6 days prior to enrollment;~11. Known or suspected impairment/alteration of the immune system, immunosuppressive therapy;~12. Receipt of blood, blood products and/or plasma derivatives, or a parenteral immunoglobulin preparation within the previous 90 days;~13. History of severe allergic reactions after previous vaccinations or hypersensitivity to any vaccine component;~14. Receipt of or intent to immunize with any other vaccine(s) within 30 days prior and throughout the study period;~15. Participation in another clinical trial within the last 90 days or planned for during study.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- rMenB (Type: EXPERIMENTAL): Subjects received two doses of rMenB+OMV NZ vaccine (at Day 1 and Day 31) in the study.
- Placebo/MenACWY (Type: ACTIVE_COMPARATOR): Subjects received one dose of saline placebo (Day 1) and one dose of MenACWY-CRM vaccine (Day 31) in the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Preoperative Administration of Paracetamol-codeine on Pain Following Impacted Mandibular Third Molar Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* absence of systemic pathologies (ASA class I);~* non-smoker;~* not pregnant or lactating;~* good oral hygiene;~* no drug consumption for 10 days before the operation;~* bilateral impacted mandibular third molars with comparable position, depth and inclination;~* presence of the first and second molars;~* absence of painful symptoms and associated inflammatory or osteolytic pathologies in a radiographic examination;~* extraction difficulty index of \>7 according to Pederson's scale and a degree of IV (complex procedures) on a modified version of Parant's scale.~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- analgesic group (Type: ACTIVE_COMPARATOR): preoperative oral dose of paracetamol-codeine
- placebo group (Type: PLACEBO_COMPARATOR): preoperative placebo (starch)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Extension Study Of RN624

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Enrolled in Study RN624-CL006~Exclusion Criteria:~* The occurrence of any adverse event or condition during the controlled studies that, in the opinion of the Investigator, should exclude the subject from participating in the open-label extension~* Pregnant or lactating female subjects or subjects who do not agree to use an appropriate form of birth control throughout the study and for 3 months after completing the study

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete